Shanghai Cell Therapy Group Pharmaceutical Technology

Shanghai Cell Therapy Group (SCTG) is a vertically integrated biotechnology company headquartered in Shanghai, China, dedicated to the development and commercialization of advanced cell therapies. The company operates a unique closed-loop model that encompasses cell storage, research and development, clinical trials, and specialized hospital care through its own medical facilities. SCTG's proprietary White-Ze CAR-T platform leverages nanobody technology to target both liquid and solid tumors, with its lead candidate BZ019 currently in mid-stage clinical development for lymphoma. Beyond therapeutics, the group maintains one of the world's largest immune cell banks and provides CDMO services for cell-based products. SCTG aims to reduce the cost of CAR-T treatments through technological innovation and large-scale automated manufacturing.